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Background
Since its approval in 2011 for treatment of systemic
juvenile idiopathic arthritis (JIA), tocilizumab treatments
are followed by the German biologics register (BiKeR).
The aim of this interim analysis is to evaluate the effi-
cacy and safety of tocilizumab under practical conditions
in childhood.
Methods
Demographics, clinical characteristics, previous and con-
comitant therapy, parameters of disease activity and
adverse events were documented prospectively. The effi-
cacy was based on the PedACR 30/50/70/90 criteria and
the JADAS10. Tolerability was captured by the primary
treating physician to the adverse event reports.
Results
Until 31.12.2014 60 sJIA patients were included in
BiKeR in which treatment with tocilizumab was started.
The mean age at onset was 4.6 (median 3.3) years and
the mean age at baseline was 9.4 (median 9.8) years and
mean disease duration was 4.7 (median 3.6) years. Only
20.3% of patients were treated with tocilizumab in the
first two years of their disease. Pre-treatment with
NSAIDs was carried out at 52 (86.7%), with steroids in
58 (96.7%), with methotrexate in 53 (88.3%). 26 treat-
ment attempts with other DMARDs, most commonly
with azathioprine (9; 15%) or CSA (9; 15%) and 44 ther-
apeutic trials with other biologics were made. Etanercept
was used most frequently (25; 41.7%) followed by ana-
kinra (23.3%; 14). Concomitant therapy consisted of
NSAIDs (38; 63%), steroids (42; 70%) and methotrexate
(38; 63.3%) with other DMARDs only in individual
cases.
Most patients showed a significant response to treat-
ment. At last documentation 62% / 58% / 50% reached
a JIA ACR30/50/70 response. The mean JADAS10
showed a decrease from 17.5 to 6.0 / 3.0 / 4.0 / 3.0 / 4.0
after 3/6/12/18/24 months. The proportion of patients
in remission (JADAS10≤1) at month 6, 12, 24 was 42% /
25% / 27%, and the proportion in JADAS minimal dis-
ease actvity, MDA (JADAS10≤3,8) 55%, 35% and 55%.
Until 31.12.2014 a total of 74 adverse events (AE)
were reported (101.7 / 100 patient-years (CI 81.0 to
127.8)), of which 10 (13.7/100 patient-years (CI 7.4 to
25, 5)) were serious (SAE). Infections were reported
most frequently with 33 events. 5 AEs related cytopenias
(without MAS), 4 intolerance reactions. 3 infections
were SAE (appendicitis, pneumonia, herpes zoster).
4 patients developed a macrophage activation syndrome.
Further SAE occurred once, anaphylaxis, seizure, frac-
ture. Opportunistic infections, including tuberculosis,
malignancies or deaths were not reported. In 32 patients
(53.3%) the treatment was stopped. Reasons were (sev-
eral simultaneously possible) remission in 15 (25%), inef-
fectiveness 7 (11.7%), patient request 5 (8.3%),
intolerance 4 (6.7%) other 1 (1.7%).
Summary
Upon therapy with tocilizumab a high ACR response was
achieved by many sJIA patients, as well as a JADAS
MDA. A JADAS remission was documented in up to 40%
of patients. In many patients, tocilizumab was used late
and as second biologic. The tolerability was good overall
and comparable to those of other biologics in JIA. Only a
few patients discontinued therapy because of intolerance
or side effects.
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